Skip to main content

Security report for vfa.de

Verband Forschender Arzneimittelhersteller e.V. · Healthcare · Germany

Medium risk. 5 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

65/100

Risk levelMedium

0–100, higher is better. How it is calculated

The Verband Forschender Arzneimittelhersteller e.V. (vfa) is a prominent German pharmaceutical industry association representing leading research-based pharmaceutical companies. The website serves as a comprehensive platform providing information on pharmaceutical research, health policy, economic topics, and member services. It targets pharma companies, healthcare professionals, patients, and policymakers, positioning itself as a key industry voice in Germany. The site features professional design, clear navigation, and extensive content relevant to its audience. Technically, the site employs modern web technologies including Bootstrap, jQuery, and Google Tag Manager, with good mobile optimization and accessibility. Security posture is strong with HTTPS enforced, secure login forms, and cookie consent management, though explicit security headers and policies could be enhanced. Overall, the site is trustworthy, compliant with GDPR, and professionally maintained, supporting the vfa's role as a leading industry association.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

5 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  3. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      SSL Certificate Expires Soon

      SSL certificate expires in 16 days

      What to do: Renew SSL certificate before expiration

      • NIS2 21(2)(h)
      • IR 2024/2690 9.2(c): Implementing Regulation (EU) 2024/2690, Annex point 9.2(c): Cryptography
      • NIST SC-17: NIST SP 800-53 Rev. 5 SC-17: Public Key Infrastructure Certificates

Need hands-on remediation? Email guard@offseq.com

Keep watching vfa.de

This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
35
Email security
60
DNS health
65
Network security
100
GDPR outside view
68
Average
65

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention vfa.de, from OffSeq Breach.

No leaked records found

Breach holds no records for vfa.de right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The vfa holds a significant market position representing over half of the German pharmaceutical market through its 50 member companies and their subsidiaries. Its business model focuses on advocacy, research promotion, and information dissemination within the healthcare sector. The website reflects a mature digital presence with multiple portals, multimedia content, and social media integration, indicating active engagement with stakeholders. Partnerships such as 'starkamstandort.de' are highlighted, supporting innovation and industry collaboration. The association's focus on topics like AMNOG, orphan drugs, and clinical studies underscores its role in shaping pharmaceutical policy and public discourse in Germany.

Security posture

The website demonstrates a solid security foundation with HTTPS encryption, secure login mechanisms, and a comprehensive cookie consent management system (Klaro). No critical vulnerabilities or exposed sensitive data were detected in the HTML content. However, the absence of explicit security headers such as Content-Security-Policy and X-Frame-Options suggests room for improvement. There is no publicly available security policy or incident response contact information, which could enhance transparency and preparedness. Overall, the security posture is good but could benefit from formalized policies and additional HTTP security headers.

Recommendations

  1. Implement and enforce HTTP security headers including Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to mitigate common web attacks.
  2. Publish a clear security policy and provide dedicated incident response contact channels (e.g., security@ or abuse@ email addresses).
  3. Regularly audit and update third-party scripts and libraries to avoid vulnerabilities.
  4. Enhance HTTPS configuration by adding Strict-Transport-Security (HSTS) headers if not already present.
  5. Maintain and update privacy and cookie policies to reflect evolving regulations and best practices.

Contact details published on the site

Addresses
Legal name
Verband Forschender Arzneimittelhersteller e.V.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Verband Forschender Arzneimittelhersteller e.V.
Description
Der vfa ist der Verband der forschenden Pharma-Unternehmen in Deutschland. Er vertritt die Interessen von 50 weltweit führenden Herstellern und ihren rund 90 Tochter- und Schwesterfirmen in der Gesundheits-, Forschungs- und Wirtschaftspolitik.
Key services
Advocacy, Information dissemination, Research promotion, Member services, Public relations
Content quality
excellent
Branding
consistent

Technology

Stack
HTML5, CSS3, JavaScript, jQuery, Bootstrap, FontAwesome, Google Tag Manager, Klaro Consent Manager
Frameworks
Bootstrap
Performance
moderate
Mobile
excellent
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Secure login forms with POST method
  • Cookie consent management implemented
  • No exposed sensitive data in HTML
  • No inline JavaScript vulnerabilities detected

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Ad networks
Google Ads
Tracking pixels
VG-Wort
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content and navigation.
  2. Strong compliance with GDPR and cookie consent requirements.
  3. Professional and consistent branding and design.
  4. Secure login area for members with encrypted cookie login.
  5. Extensive information about pharmaceutical research and industry topics.
  6. Multiple social media and external links to reputable platforms.
  7. No signs of malware, phishing, or suspicious content.
  8. No explicit security policy or incident response contacts found.
  9. No terms of service page detected.
  10. Use of modern web technologies and frameworks.
Technical notes

Notes

The website is built using standard modern web technologies such as HTML5, CSS3, JavaScript, jQuery, and Bootstrap, ensuring responsive and accessible design. It integrates Google Tag Manager for analytics and Klaro for consent management, reflecting a mature approach to privacy compliance. The site loads a minified CSS and JavaScript bundle, indicating optimization efforts. Performance is moderate with good mobile responsiveness and accessibility features. No CMS was explicitly detected, suggesting a custom or proprietary solution. Hosting provider details are not disclosed. The site structure is clear with well-organized navigation and multiple content portals, supporting a positive user experience.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Earlier scans of this domain

  1. 68/100Medium32 findingsView report
Reviews of this site

Share your experience with vfa.de. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review vfa.de.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.